文献
J-GLOBAL ID:201702217729108701
整理番号:17A1168430
選択的代謝型グルタミン酸受容体5きっ抗薬mavoglurant(AFQ056)は中等度から重度の胃食道逆流疾患のイヌと患者における逆流症状発現の発生率を低下させる【Powered by NICT】
The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease
著者 (10件):
Rouzade-Dominguez M.-L.
(Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland)
,
Pezous N.
(Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland)
,
David O. J.
(Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland)
,
Tutuian R.
(Universitaetsspital Zuerich, Zuerich, Switzerland)
,
Bruley des Varannes S.
(CHU-Hotel Dieu Nantes, Nantes, France)
,
Tack J.
(University Hospitals Leuven, Leuven, Belgium)
,
Malfertheiner P.
(Universitaetsklinikum Magdeburg, Magdeburg, Germany)
,
Allescher H.-D.
(Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany)
,
Ufer M.
(Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland)
,
Ruehl A.
(Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland)
資料名:
Neurogastroenterology & Motility
(Neurogastroenterology & Motility)
巻:
29
号:
8
ページ:
ROMBUNNO.13058
発行年:
2017年
JST資料番号:
W2694A
ISSN:
1350-1925
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)